Cardiovascular disease remains the leading cause of mortality worldwide, with aging serving as the primary risk factor. As we age, the heart and blood vessels undergo progressive changes—including increased arterial stiffness, impaired relaxation (diastolic dysfunction), and a decline in endothelial health—often long before clinical symptoms appear. Rapamycin, an FDA-approved compound originally used in organ transplantation,…

Instead of watching our canine companions succumb to the inevitable decline of age-related disease, the rapidly advancing field of canine geroscience is proactively targeting the biological roots of aging. At the forefront of this movement is a highly targeted pharmacological intervention: using rapamycin to selectively inhibit the mechanistic target of rapamycin (mTOR) pathway. By dialing…

"They might increase lifespan by a little bit or they might increase it by a lot,” says Tahlia Fulton at the University of Sydney in Australia. Introduction The quest to extend healthy human lifespan has long captivated biomedical science, yet few interventions have generated as much rigorous scientific interest as rapamycin. First described in the 1970s as…

Rapamycin has gone from being a life-saving drug for transplant patients to one of the most intriguing candidates for slowing aging. As more research uncovers new rapamycin benefits, scientists are now exploring its role in cellular rejuvenation, metabolic repair, and even reproductive health. Beyond the headlines, new discoveries continue to shape how we think about…

A medication once reserved for preventing organ rejection, rapamycin is now gaining momentum in the field of longevity and rapamycin for anti-aging research. Initially created as an immunosuppressive drug, rapamycin is now being studied for its potential to slow aging and support rapamycin lifespan extension in humans. With growing scientific support pointing to its possible…